Page last updated: 2024-10-30

metformin and Carcinoma, Basal Cell, Pigmented

metformin has been researched along with Carcinoma, Basal Cell, Pigmented in 8 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"Metformin was associated with a lower risk of developing BCC (OR, 0."1.62Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland. ( Adalsteinsson, JA; Feng, H; Jonasson, JG; Kristjansson, AK; Muzumdar, S; Olafsdottir, GH; Ratner, D; Silverberg, JI; Tryggvadottir, L; Ungar, J; Waldman, R; Wu, R, 2021)

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (25.00)24.3611
2020's6 (75.00)2.80

Authors

AuthorsStudies
Misitzis, A3
Stratigos, A1
Mastorakos, G2
Weinstock, M1
Ravishankar, A1
Zhang, T1
Lindgren, BR1
Farah, RS1
Dong, Z1
Goldfarb, NI1
Stratigos, AJ1
Beatson, M1
Dellavalle, RP1
Weinstock, MA2
Adalsteinsson, JA2
Muzumdar, S1
Waldman, R2
Wu, R1
Ratner, D2
Feng, H2
Ungar, J1
Silverberg, JI1
Olafsdottir, GH1
Kristjansson, AK1
Tryggvadottir, L2
Jonasson, JG2
Zhang, Y1
Storr, SJ1
Johnson, K1
Green, AR1
Rakha, EA1
Ellis, IO1
Morgan, DA1
Martin, SG1
Byekova, YA1
Herrmann, JL1
Xu, J1
Elmets, CA1
Athar, M1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial[NCT00847912]Phase 4954 participants (Actual)Interventional2009-06-26Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Hazard Ratio for Surgically Treated KC

(NCT00847912)
Timeframe: date of randomization to last visit before end of study follow up (6/30/2013), assessed up to four years

Interventionparticipants (Number)
Arm 1: 5-fluorouracil182
Arm 2: Placebo, Vehicle Control177

The Time to Diagnosis of the First Keratinocyte Carcinoma (KC) on the Face or Ears for Which Surgery is Performed

Diagnosis of the first Primary Basil Cell Carcinoma (BCC) or primary Squamous Cell Carcinoma (SCC) on the face or ears that was removed surgically. (NCT00847912)
Timeframe: From randomization to last visit prior to end of study date (6/30/2013), assessed up to four years

Interventionyears (Median)
Arm 1: 5-fluorouracil3.37
Arm 2: Placebo, Vehicle Control3.52

Trials

1 trial available for metformin and Carcinoma, Basal Cell, Pigmented

ArticleYear
Antidiabetic Treatment in Patients at High Risk for a Subsequent Keratinocyte Carcinoma.
    Journal of drugs in dermatology : JDD, 2022, May-01, Volume: 21, Issue:5

    Topics: Aged; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Diabetes Mellitus, Type 2; Female; Humans; Hy

2022

Other Studies

7 other studies available for metformin and Carcinoma, Basal Cell, Pigmented

ArticleYear
The effect of metformin on the risk of recurrent nonmelanoma skin cancers.
    International journal of dermatology, 2020, Volume: 59, Issue:8

    Topics: Carcinoma, Basal Cell; Humans; Metformin; Neoplasm Recurrence, Local; Skin Neoplasms

2020
The association of metformin use with keratinocyte carcinoma development in high-risk patients.
    Dermatologic therapy, 2020, Volume: 33, Issue:6

    Topics: Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms

2020
Metformin is associated with decreased risk of basal cell carcinoma: A whole-population case-control study from Iceland.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:1

    Topics: Aged; Aged, 80 and over; Carcinoma, Basal Cell; Case-Control Studies; Female; Hedgehog Proteins; Hum

2021
Reply to: Metformin use and keratinocyte carcinoma risk.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:4

    Topics: Carcinoma, Basal Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms

2021
Metformin use and keratinocyte carcinoma risk.
    Journal of the American Academy of Dermatology, 2021, Volume: 85, Issue:4

    Topics: Carcinoma, Basal Cell; Humans; Keratinocytes; Metformin; Skin Neoplasms

2021
Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy.
    Oncotarget, 2014, Dec-30, Volume: 5, Issue:24

    Topics: AMP-Activated Protein Kinases; Breast Neoplasms; Carcinoma, Basal Cell; Cell Line, Tumor; Chemoradio

2014
Liver kinase B1 (LKB1) in the pathogenesis of UVB-induced murine basal cell carcinoma.
    Archives of biochemistry and biophysics, 2011, Apr-15, Volume: 508, Issue:2

    Topics: Adenylate Kinase; AMP-Activated Protein Kinases; Animals; Carcinoma, Basal Cell; Cell Cycle Proteins

2011
chemdatabank.com